New York, NY – April 28, 2026 – Ambio Pharm Inc., a biotechnology company focused on advanced peptide research and development, today announced the successful completion of Phase I human trials and the upcoming limited release of its lead compound, SCAM-47 (Synthetic Colloidally Aggregating Motif-47).
Developed over eight years in collaboration with researchers from Stanford University School of Medicine and a consortium of independent laboratories in Singapore, SCAM-47 is a 47-amino-acid cyclic peptide engineered to simultaneously influence multiple healing and metabolic pathways. Early findings suggest it may represent a meaningful advancement in performance recovery and age-related tissue degeneration research.
Mechanism of Action
SCAM-47 functions as a selective agonist at both the ghrelin receptor and specific integrin-binding sites, while incorporating a novel “colloidal aggregation motif” designed to enhance localized bioavailability at sites of injury.
In preclinical models, the peptide demonstrated the ability to upregulate VEGF, IGF-1, and collagen type I expression without the systemic effects commonly associated with traditional growth hormone secretagogues. Researchers informally nicknamed the molecule “SCAM” during development due to its unexpectedly broad activity profile during early screening—a label that ultimately remained.
Clinical Trial Highlights
In a randomized, double-blind, placebo-controlled Phase I study involving 48 healthy adult volunteers (ages 25–55), participants receiving daily subcutaneous doses of 250–500 mcg of SCAM-47 over 28 days demonstrated:
- 312% average improvement in tendon and ligament repair markers (measured via ultrasound elastography) compared to placebo
- Statistically significant reduction in visceral adipose tissue (average 4.7% decrease via DEXA scan) with no measurable loss of lean muscle mass
- Accelerated wound healing by 41% in standardized dermal injury models
- Self-reported improvements in sleep quality, cognitive clarity, and exercise recovery time
- No serious adverse events; mild injection-site redness was the most commonly reported side effect, resolving within 48 hours
“These results exceeded our expectations,” said Senior Quality & Regulatory Advisor at Ambio Pharm Inc. “It appears to influence the body’s repair processes at a cellular level. We are particularly interested in its potential applications within sports medicine, post-surgical recovery, and age-related muscle decline.” via his X/Twitter @brant_zell
Safety and Dosing
SCAM-47 is supplied as a lyophilized powder in 10 mg vials for reconstitution. Standard research dosing during trials ranged from 300–600 mcg per day, administered via subcutaneous injection.
The compound demonstrated strong stability under refrigerated conditions, with a projected shelf life of up to 24 months.
Availability
Beginning May 15, 2026, SCAM-47 will be made available exclusively for research and investigational purposes through authorized compounding partners and select research distributors. It will carry the standard designation:
“For Research Use Only – Not for Human Consumption.”
Ambio Pharm Inc. plans to initiate Phase II trials later this year, focusing on rotator cuff injuries and metabolic syndrome, with the long-term objective of exploring regulatory pathways in key markets.
About Ambio Pharm Inc.
Ambio Pharm Inc. is a biotechnology company engaged in the research and development of peptide-based compounds targeting regenerative medicine and metabolic health. With a focus on precision formulation and emerging therapeutic pathways, the company works with global research partners to advance investigational compounds for scientific and clinical exploration.
